These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31910893)

  • 1. Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry.
    Gavigan K; Nowell WB; Serna MS; Stark JL; Yassine M; Curtis JR
    Arthritis Res Ther; 2020 Jan; 22(1):4. PubMed ID: 31910893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology.
    Yun H; Nowell WB; Curtis D; H Willig J; Yang S; Auriemma M; Chen L; Filby C; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):553-560. PubMed ID: 30927515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories.
    Pincus T; Swearingen CJ; Bergman M; Yazici Y
    J Rheumatol; 2008 Nov; 35(11):2136-47. PubMed ID: 18793006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of self-report questionnaires for assessing rheumatoid arthritis activity: a cross-sectional study of RAPID3 and RADAI5 and flare detection in 200 patients.
    Bossert M; Prati C; Vidal C; Bongain S; Toussirot E; Wendling D
    Joint Bone Spine; 2012 Jan; 79(1):57-62. PubMed ID: 21550283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(2):e001050. PubMed ID: 31908842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis.
    Harrold LR; Zueger P; Nowell WB; Blachley T; Schrader A; Lakin PR; Curtis D; Stradford L; Venkatachalam S; Tundia N; Patel PA
    Rheumatol Ther; 2023 Dec; 10(6):1519-1533. PubMed ID: 37728861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
    Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
    Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort.
    Castrejón I; Dougados M; Combe B; Guillemin F; Fautrel B; Pincus T
    J Rheumatol; 2013 Apr; 40(4):386-93. PubMed ID: 23378463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA).
    Barroso N; Woodworth TG; Furst DE; Guillemin F; Fautrel BJ; Borazan N; Kafaja S; Brook J; Elashoff DA; Ranganath VK
    Clin Rheumatol; 2020 Jan; 39(1):189-199. PubMed ID: 31493148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year maintenance with routine assessment of patient index data 3-based remission may inhibit radiographic progression in patients with rheumatoid arthritis treated with routine clinical therapy: A retrospective comparison of radiographic outcome and its prognostic factors between maintained remissions with patient-reported outcome index and physician-oriented disease activity indices.
    Katayama K; Okubo T; Sato T; Kamiya K; Fukai R; Abe S; Ito H; Makino Y; Kamishima T
    Mod Rheumatol; 2016 Nov; 26(6):817-827. PubMed ID: 26915909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology.
    Yun H; Chen L; Xie F; Patel H; Boytsov N; Zhang X; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):166-175. PubMed ID: 31566905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
    Pincus T
    Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate.
    Castrejón I; Pincus T; Soubrier M; Lin YC; Rat AC; Combe B; Dougados M
    Rheumatology (Oxford); 2013 Oct; 52(10):1890-7. PubMed ID: 23864169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study assessing the novel use of musculoskeletal ultrasound in patients with rheumatoid arthritis to improve patient attitudes and adherence to medication.
    Joplin SK; van der Zwan R; Bagga H; Joshua F; Wong PK
    Int J Rheum Dis; 2016 Jul; 19(7):658-64. PubMed ID: 24839920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials.
    Pincus T; Hines P; Bergman MJ; Yazici Y; Rosenblatt LC; MacLean R
    J Rheumatol; 2011 Dec; 38(12):2565-71. PubMed ID: 22089467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.
    Khawaja MN; Bergman MJ; Yourish J; Pei J; Reiss W; Keystone E
    Arthritis Care Res (Hoboken); 2017 May; 69(5):609-615. PubMed ID: 27564431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis.
    Owensby JK; Chen L; O'Beirne R; Ruderman EM; Harrold LR; Melnick JA; Safford MM; Curtis JR; Danila MI
    Arthritis Care Res (Hoboken); 2020 Jul; 72(7):933-941. PubMed ID: 31008566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies.
    Kremer JM; Pappas DA; Kane K; Greenberg J; Harrold LR; Feathers VL; Shadick N; Weinblatt ME; Reed G
    J Rheumatol; 2021 Dec; 48(12):1776-1783. PubMed ID: 33323534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
    Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the Virtual Monitoring Clinic, a novel nurse-led service for monitoring patients with stable rheumatoid arthritis.
    Chew LC; Xin X; Yang H; Thumboo J
    Int J Rheum Dis; 2019 Apr; 22(4):619-625. PubMed ID: 30450812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.